The recommendation follows an October review of interim Phase 1 data, which indicated the vaccine was well tolerated and triggered promising protective immune responses. The Coalition for Epidemic Preparedness Innovations, having previously provided $58.5 million for initial development, is backing the next stage of the study.

Moderna CEO Stéphane Bancel cited the development as a validation of the company's mRNA platform, emphasizing its utility in responding to emerging infectious diseases. Following the announcement, Moderna shares climbed 8.2% to $247.23 during Wednesday trading, building on a year of significant growth driven by the company’s separate progress in melanoma vaccine research.